全身性糖皮质激素治疗耳鼻咽喉头颈外科疾病:面向临床医生的循证入门指南
该综述通过检索PubMed、Cochrane图书馆及美国耳鼻咽喉头颈外科学会临床实践指南,截至2021年11月的文献,汇总全身性糖皮质激素治疗耳鼻咽喉科常见疾病的证据。结论认为不同疾病证据差异大:贝尔面瘫、鼻窦息肉病和下气道疾病有高级别证据支持;上呼吸道感染、咽鼓管功能障碍等证据弱或缺乏;多种疾病证据不确定。临床应基于循证视角处方,并考虑替代给药途径。
要点
- 贝尔面瘫、鼻窦息肉病和下气道疾病有高级别证据支持全身性糖皮质激素使用。
- 上呼吸道感染、咽鼓管功能障碍、良性阵发性位置性眩晕等证据弱或缺乏。
- 临床处方应基于循证视角,考虑喷雾、滴剂、吸入剂等替代途径。
核心结论
- 全身性糖皮质激素在不同耳鼻咽喉疾病中的有效性证据差异很大。
- 高级别证据支持用于贝尔面瘫、鼻窦息肉病和下气道疾病。
- 上呼吸道感染、咽鼓管功能障碍、良性阵发性位置性眩晕、腺扁桃体肥大或非过敏性鼻炎证据弱或缺乏。
- 急性喉炎、急性咽炎、急性鼻窦炎、血管性水肿、不伴息肉的慢性鼻窦炎、梅尼埃病、病毒感染后嗅觉丧失、术后神经轻瘫/瘫痪、面部疼痛和突发性感音神经性听力损失证据不确定。
研究设计与样本
- 综述检索PubMed、Cochrane图书馆和美国耳鼻咽喉头颈外科学会临床实践指南。
- 全面检索截至2021年11月的已发表文献,评估全身性糖皮质激素单用或联合其他治疗的有效性。
- 优先检索临床实践指南、系统评价和随机对照试验,汇编干预与结局并生成汇总表和叙述性综合。
主要发现
- 证据有效性因疾病而异,高级别证据仅支持贝尔面瘫、鼻窦息肉病和下气道疾病。
- 上呼吸道感染、咽鼓管功能障碍、良性阵发性位置性眩晕、腺扁桃体肥大或非过敏性鼻炎证据弱或缺乏。
- 急性喉炎、急性咽炎、急性鼻窦炎、血管性水肿、不伴息肉的慢性鼻窦炎、梅尼埃病、病毒感染后嗅觉丧失、术后神经轻瘫/瘫痪、面部疼痛和突发性感音神经性听力损失证据不确定。
关键数值与推荐
- 高级别证据支持全身性糖皮质激素用于贝尔面瘫、鼻窦息肉病和下气道疾病。
- 证据弱或缺乏的疾病包括上呼吸道感染、咽鼓管功能障碍、良性阵发性位置性眩晕、腺扁桃体肥大和非过敏性鼻炎。
- 证据不确定的疾病包括急性喉炎、急性咽炎、急性鼻窦炎、血管性水肿、不伴息肉的慢性鼻窦炎、梅尼埃病、病毒感染后嗅觉丧失、术后神经轻瘫/瘫痪、面部疼痛和突发性感音神经性听力损失。
临床怎么用
- 临床医生应以循证视角处方全身性糖皮质激素,就风险、预期获益和长期影响的有限数据向患者提供咨询。
- 对于许多疾病,尤其是自限性或需长期治疗的疾病,替代给药途径如喷雾、滴剂、吸入剂和病灶内注射可能更可取。
- 审慎使用全身性糖皮质激素可降低药物相关不良事件风险。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To offer pragmatic, evidence-informed guidance on the use of systemic corticosteroids (SCS) for common otolaryngologic disorders. DATA SOURCES: PubMed, Cochrane Library, and American Academy of Otolaryngology-Head and Neck Surgery Foundation clinical practice guidelines. REVIEW METHODS: A comprehensive search of published literature through November 2021 was conducted on the efficacy of SCS, alone or in combination with other treatments, for managing disorders in otolaryngology and the subdisciplines. Clinical practice guidelines, systematic reviews, and randomized controlled trials, when available, were preferentially retrieved. Interventions and outcomes of SCS use were compiled to generate summary tables and narrative synthesis of findings. CONCLUSIONS: Evidence on the effectiveness of SCS varies widely across otolaryngology disorders. High-level evidence supports SCS use for Bell's palsy, sinonasal polyposis, and lower airway disease. Conversely, evidence is weak or absent for upper respiratory tract infection, eustachian tube dysfunction, benign paroxysmal positional vertigo, adenotonsillar hypertrophy, or nonallergic rhinitis. Evidence is indeterminate for acute laryngitis, acute pharyngitis, acute sinusitis, angioedema, chronic rhinosinusitis without polyps, Ménière's disease, postviral olfactory loss, postoperative nerve paresis/paralysis, facial pain, and sudden sensorineural hearing loss. IMPLICATIONS FOR PRACTICE: Clinicians should bring an evidence-informed lens to SCS prescribing to best counsel patients regarding the risks, anticipated benefits, and limited data on long-term effects. Alternate routes of corticosteroid administration-such as sprays, drops, inhalers, and intralesional injections-may be preferable for many disorders, particularly those that are self-limited or require a prolonged duration of therapy. Prudent use of SCS reduces the risk of medication-related adverse effects. Clinicians who are conversant with high-level evidence can achieve optimal outcomes and stewardship when prescribing SCS.
引用
- McCoul ED, Megwalu UC, Joe S, et al. Systemic Steroids for Otolaryngology-Head and Neck Surgery Disorders: An Evidence-Based Primer for Clinicians. Otolaryngol Head Neck Surg. 2023. PMID: 35349383. doi:10.1177/01945998221087664
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。